ImmuCell Corporation (ICCC)
USD 5.32
(5.05%)
USD 5.32
(5.05%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.5 Million USD | -8.92% |
| 2022 | 349.99 Thousand USD | -994.55% |
| 2021 | 2.71 Million USD | 118.62% |
| 2020 | 1.64 Million USD | -44.65% |
| 2019 | 1.43 Million USD | 66.49% |
| 2018 | 88.44 Thousand USD | -1071.6% |
| 2017 | 684.52 Thousand USD | -114.11% |
| 2016 | 1.72 Million USD | -35.56% |
| 2015 | 2.64 Million USD | 963.7% |
| 2014 | 251.29 Thousand USD | -42.78% |
| 2013 | 692.04 Thousand USD | -34.45% |
| 2012 | 672.81 Thousand USD | 436.13% |
| 2011 | -192.31 Thousand USD | 18.62% |
| 2010 | -241.9 Thousand USD | -133.64% |
| 2009 | -4065.00 USD | 86.4% |
| 2008 | -768.49 Thousand USD | -146.28% |
| 2007 | 1.66 Million USD | 58.08% |
| 2006 | 1.04 Million USD | -33.15% |
| 2005 | 1.58 Million USD | 294.99% |
| 2004 | 399.29 Thousand USD | 131.38% |
| 2003 | -172.76 Thousand USD | -667.13% |
| 2002 | 769.91 Thousand USD | -129.3% |
| 2001 | 847.6 Thousand USD | 3.56% |
| 2000 | 546.53 Thousand USD | -32.83% |
| 1999 | 716.5 Thousand USD | 713.64% |
| 1998 | 100 Thousand USD | -75.0% |
| 1997 | 400 Thousand USD | 300.0% |
| 1996 | - USD | -50.0% |
| 1995 | 200 Thousand USD | 200.0% |
| 1994 | -100 Thousand USD | 0.0% |
| 1993 | - USD | 100.0% |
| 1992 | -200 Thousand USD | 84.62% |
| 1991 | -1.3 Million USD | -225.0% |
| 1990 | -400 Thousand USD | 50.0% |
| 1989 | -800 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 367.2 Thousand USD | 225.33% |
| 2024 Q2 | -715.65 Thousand USD | -290.31% |
| 2023 Q3 | -1.18 Million USD | -95.13% |
| 2023 FY | - USD | -31.84% |
| 2023 Q2 | -606.81 Thousand USD | 61.06% |
| 2023 Q1 | -1.55 Million USD | 10.13% |
| 2023 Q4 | -318 Thousand USD | 73.14% |
| 2022 FY | - USD | -994.55% |
| 2022 Q4 | -1.73 Million USD | -181.05% |
| 2022 Q1 | 1.42 Million USD | 768.5% |
| 2022 Q2 | 36.62 Thousand USD | -97.43% |
| 2022 Q3 | -617 Thousand USD | -1784.69% |
| 2021 Q4 | 163.8 Thousand USD | -81.69% |
| 2021 Q3 | 894.77 Thousand USD | 6.16% |
| 2021 Q2 | 842.83 Thousand USD | 240.12% |
| 2021 FY | - USD | 118.62% |
| 2021 Q1 | 247.8 Thousand USD | 139.09% |
| 2020 Q2 | -115.71 Thousand USD | -115.03% |
| 2020 Q4 | -634 Thousand USD | -279.18% |
| 2020 FY | - USD | -44.65% |
| 2020 Q3 | 353.84 Thousand USD | 405.8% |
| 2020 Q1 | 769.95 Thousand USD | 418.16% |
| 2019 Q1 | 836.2 Thousand USD | 190.3% |
| 2019 FY | - USD | 66.49% |
| 2019 Q2 | -547 Thousand USD | -165.41% |
| 2019 Q3 | 179.4 Thousand USD | 132.8% |
| 2019 Q4 | -242 Thousand USD | -234.89% |
| 2018 Q4 | -926 Thousand USD | -99.87% |
| 2018 Q3 | -463.29 Thousand USD | -586.69% |
| 2018 Q2 | 95.19 Thousand USD | -13.79% |
| 2018 Q1 | 110.41 Thousand USD | 126.74% |
| 2018 FY | - USD | -1071.6% |
| 2017 Q1 | 1.14 Million USD | 252.63% |
| 2017 FY | - USD | -114.11% |
| 2017 Q4 | -413 Thousand USD | -54.28% |
| 2017 Q3 | -267.7 Thousand USD | -484.99% |
| 2017 Q2 | -45.76 Thousand USD | -103.99% |
| 2016 Q1 | 884.33 Thousand USD | 43.18% |
| 2016 FY | - USD | -35.56% |
| 2016 Q4 | 325.01 Thousand USD | 22.19% |
| 2016 Q3 | 265.99 Thousand USD | 7.67% |
| 2016 Q2 | 247.04 Thousand USD | -72.06% |
| 2015 Q4 | 617.63 Thousand USD | -18.96% |
| 2015 FY | - USD | 963.7% |
| 2015 Q1 | 944.05 Thousand USD | 196.8% |
| 2015 Q3 | 762.15 Thousand USD | 118.25% |
| 2015 Q2 | 349.2 Thousand USD | -63.01% |
| 2014 Q2 | -344.32 Thousand USD | -366.51% |
| 2014 FY | - USD | -42.78% |
| 2014 Q4 | 318.08 Thousand USD | 114.43% |
| 2014 Q3 | 148.33 Thousand USD | 143.08% |
| 2014 Q1 | 129.19 Thousand USD | 212.51% |
| 2013 Q4 | -114.83 Thousand USD | -95.55% |
| 2013 Q1 | 485.76 Thousand USD | 372.65% |
| 2013 Q2 | 126.94 Thousand USD | -73.87% |
| 2013 FY | - USD | -34.45% |
| 2013 Q3 | -58.72 Thousand USD | -146.26% |
| 2012 FY | - USD | 436.13% |
| 2012 Q4 | 102.77 Thousand USD | 674.78% |
| 2012 Q3 | 13.26 Thousand USD | -91.11% |
| 2012 Q2 | 149.17 Thousand USD | -61.77% |
| 2012 Q1 | 390.16 Thousand USD | 210.2% |
| 2011 Q2 | -317.61 Thousand USD | -437.95% |
| 2011 Q1 | 93.98 Thousand USD | 183.63% |
| 2011 Q3 | -97.09 Thousand USD | 69.43% |
| 2011 Q4 | 125.77 Thousand USD | 229.55% |
| 2011 FY | - USD | 18.62% |
| 2010 FY | - USD | -133.64% |
| 2010 Q1 | 30.69 Thousand USD | 61.75% |
| 2010 Q2 | 58.1 Thousand USD | 89.28% |
| 2010 Q3 | -243.97 Thousand USD | -519.88% |
| 2010 Q4 | -112.37 Thousand USD | 53.94% |
| 2009 Q2 | -213.48 Thousand USD | -843.37% |
| 2009 Q1 | 28.71 Thousand USD | 115.0% |
| 2009 Q4 | 18.97 Thousand USD | -68.87% |
| 2009 FY | - USD | 86.4% |
| 2009 Q3 | 60.96 Thousand USD | 128.56% |
| 2008 Q3 | -453 Thousand USD | -53.26% |
| 2008 Q4 | -191.41 Thousand USD | 57.75% |
| 2008 FY | - USD | -146.28% |
| 2008 Q1 | 169.03 Thousand USD | 1.39% |
| 2008 Q2 | -295.57 Thousand USD | -274.86% |
| 2007 Q1 | 553.67 Thousand USD | 314.34% |
| 2007 Q2 | -17.02 Thousand USD | -103.08% |
| 2007 Q4 | 166.72 Thousand USD | -82.68% |
| 2007 Q3 | 962.45 Thousand USD | 5751.86% |
| 2007 FY | - USD | 58.08% |
| 2006 Q2 | 96.24 Thousand USD | -83.62% |
| 2006 Q4 | 133.62 Thousand USD | -60.63% |
| 2006 Q3 | 339.44 Thousand USD | 252.69% |
| 2006 Q1 | 587.46 Thousand USD | 37.23% |
| 2006 FY | - USD | -33.15% |
| 2005 Q3 | 319.16 Thousand USD | 28.87% |
| 2005 Q4 | 428.07 Thousand USD | 34.12% |
| 2005 Q2 | 247.67 Thousand USD | -55.94% |
| 2005 FY | - USD | 294.99% |
| 2005 Q1 | 562.08 Thousand USD | 278.68% |
| 2004 FY | - USD | 131.38% |
| 2004 Q1 | 315.41 Thousand USD | 861.83% |
| 2004 Q2 | -73.75 Thousand USD | -123.38% |
| 2004 Q3 | 9003.00 USD | 112.21% |
| 2004 Q4 | 148.43 Thousand USD | 1548.68% |
| 2003 Q2 | -176.77 Thousand USD | 83.26% |
| 2003 FY | - USD | -667.13% |
| 2003 Q4 | -148.91 Thousand USD | 162.76% |
| 2003 Q3 | -8233.00 USD | 70.44% |
| 2003 Q1 | 69.94 Thousand USD | -278.59% |
| 2002 FY | - USD | -129.3% |
| 2002 Q4 | 305.01 Thousand USD | -1963.84% |
| 2002 Q3 | 93.5 Thousand USD | 111.59% |
| 2002 Q2 | 26.22 Thousand USD | -156.82% |
| 2002 Q1 | 345.17 Thousand USD | -41.39% |
| 2001 Q3 | -36.62 Thousand USD | -211.67% |
| 2001 Q4 | 469.21 Thousand USD | 359.33% |
| 2001 Q2 | 202.96 Thousand USD | -31.03% |
| 2001 Q1 | 212.45 Thousand USD | -40.62% |
| 2001 FY | - USD | 3.56% |
| 2000 FY | - USD | -32.83% |
| 2000 Q4 | 326.79 Thousand USD | 354.05% |
| 2000 Q3 | -63.22 Thousand USD | -743.53% |
| 2000 Q2 | 50.92 Thousand USD | -90.83% |
| 2000 Q1 | 232.04 Thousand USD | 91.77% |
| 1999 FY | - USD | 713.64% |
| 1999 Q3 | 300 Thousand USD | 200.0% |
| 1999 Q4 | 116.5 Thousand USD | -62.12% |
| 1999 Q1 | 300 Thousand USD | 0.0% |
| 1999 Q2 | 100 Thousand USD | -66.67% |
| 1998 Q1 | 100 Thousand USD | -75.0% |
| 1998 FY | - USD | -75.0% |
| 1998 Q4 | - USD | -100.0% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1997 Q3 | - USD | 100.0% |
| 1997 Q4 | 400 Thousand USD | 0.0% |
| 1997 FY | - USD | 300.0% |
| 1997 Q1 | 200 Thousand USD | -50.0% |
| 1997 Q2 | -200 Thousand USD | -200.0% |
| 1996 FY | - USD | -50.0% |
| 1996 Q4 | 400 Thousand USD | 233.33% |
| 1996 Q3 | -300 Thousand USD | 0.0% |
| 1996 Q2 | -300 Thousand USD | 0.0% |
| 1996 Q1 | - USD | -100.0% |
| 1995 FY | - USD | 200.0% |
| 1995 Q4 | 100 Thousand USD | 200.0% |
| 1995 Q3 | -100 Thousand USD | 0.0% |
| 1995 Q2 | -100 Thousand USD | -150.0% |
| 1995 Q1 | 200 Thousand USD | 300.0% |
| 1994 Q2 | 100 Thousand USD | 0.0% |
| 1994 Q4 | -100 Thousand USD | -200.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q1 | 100 Thousand USD | 200.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 Q4 | -100 Thousand USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 Q1 | - USD | 100.0% |
| 1993 FY | - USD | 100.0% |
| 1992 Q3 | -100 Thousand USD | -200.0% |
| 1992 Q2 | 100 Thousand USD | 200.0% |
| 1992 FY | - USD | 84.62% |
| 1992 Q4 | -100 Thousand USD | 0.0% |
| 1992 Q1 | -100 Thousand USD | 50.0% |
| 1991 Q1 | -500 Thousand USD | -350.0% |
| 1991 FY | - USD | -225.0% |
| 1991 Q4 | -200 Thousand USD | 60.0% |
| 1991 Q3 | -500 Thousand USD | -66.67% |
| 1991 Q2 | -300 Thousand USD | 40.0% |
| 1990 Q1 | -300 Thousand USD | -50.0% |
| 1990 FY | - USD | 50.0% |
| 1990 Q3 | -300 Thousand USD | -200.0% |
| 1990 Q4 | 200 Thousand USD | 166.67% |
| 1990 Q2 | -100 Thousand USD | 66.67% |
| 1989 Q1 | 700 Thousand USD | 0.0% |
| 1989 FY | - USD | 0.0% |
| 1989 Q3 | -100 Thousand USD | 83.33% |
| 1989 Q4 | -200 Thousand USD | -100.0% |
| 1989 Q2 | -600 Thousand USD | -185.71% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Caribou Biosciences, Inc. | -112.53 Million USD | 97.775% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 87.425% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 91.897% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 94.656% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 98.426% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 97.949% |
| Agenus Inc. | -145.92 Million USD | 98.284% |
| Fortress Biotech, Inc. | -133.64 Million USD | 98.126% |
| GlycoMimetics, Inc. | -39.12 Million USD | 93.599% |
| Novavax, Inc. | -487.39 Million USD | 99.486% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 98.354% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -760.508% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 97.308% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -680.086% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | 63.54% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 99.03% |
| AlloVir, Inc. | -190.14 Million USD | 98.683% |
| Aptorum Group Limited | -9.59 Million USD | 73.913% |
| Ardelyx, Inc. | -55.35 Million USD | 95.476% |
| Bicycle Therapeutics plc | -183.4 Million USD | 98.635% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 98.486% |
| Chimerix, Inc. | -92.97 Million USD | 97.307% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 94.365% |
| CRISPR Therapeutics AG | -202.7 Million USD | 98.765% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 89.14% |
| Precision BioSciences, Inc. | -32.04 Million USD | 92.185% |
| Dyadic International, Inc. | -8.22 Million USD | 69.573% |
| Elevation Oncology, Inc. | -41.46 Million USD | 93.961% |
| Fortress Biotech, Inc. | -133.64 Million USD | 98.126% |
| GT Biopharma, Inc. | 5.97 Million USD | 141.881% |
| Alkermes plc | 495.04 Million USD | 100.506% |
| Immix Biopharma, Inc. | -16.13 Million USD | 84.481% |
| Innoviva, Inc. | 248.96 Million USD | 101.006% |
| IO Biotech, Inc. | -91.22 Million USD | 97.255% |
| Jaguar Health, Inc. | -33.13 Million USD | 92.442% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 102.462% |
| ContextLogic Inc. | -324 Million USD | 99.227% |
| AbCellera Biologics Inc. | -192.15 Million USD | 98.697% |
| Lantern Pharma Inc. | -15.78 Million USD | 84.138% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 70.175% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 98.575% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 99.341% |
| MEI Pharma, Inc. | 26.38 Million USD | 109.492% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 96.653% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 89.615% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 98.005% |
| NextCure, Inc. | -59.03 Million USD | 95.759% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 96.762% |
| ChromaDex Corporation | -3.89 Million USD | 35.694% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 98.08% |
| Incyte Corporation | 919.42 Million USD | 100.272% |
| Opthea Limited | -200.01 Million USD | 98.748% |
| MiMedx Group, Inc. | 40.51 Million USD | 106.18% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 95.636% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 96.169% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 8.995% |
| Vaxcyte, Inc. | -464.88 Million USD | 99.461% |
| PDS Biotechnology Corporation | -40.08 Million USD | 93.753% |
| Pharming Group N.V. | 9.87 Million USD | 125.353% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 88.999% |
| Onconetix, Inc. | -36.7 Million USD | 93.178% |
| Acelyrin, Inc. | -381.52 Million USD | 99.344% |
| PureTech Health plc | -11.62 Million USD | 78.463% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 96.81% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 98.928% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 86.068% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 89.615% |
| ESSA Pharma Inc. | -26.45 Million USD | 90.535% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 85.254% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 74.879% |
| Seer, Inc. | -97.88 Million USD | 97.442% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 97.136% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 573.36% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 91.354% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -19334.213% |
| Summit Therapeutics Inc. | 1 Million USD | 350.158% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 92.5% |
| Senti Biosciences, Inc. | -61.33 Million USD | 95.917% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 98.407% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 96.474% |
| Precigen, Inc. | -89.22 Million USD | 97.194% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 95.588% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 212.039% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 97.77% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 89.45% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 59.061% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 99.536% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 95.974% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 92.284% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 91.441% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 87.578% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 95.741% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 98.546% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 63.625% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 98.789% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 102.884% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 95.111% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 74.673% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 98.942% |
| Aptose Biosciences Inc. | -52.26 Million USD | 95.209% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 97.676% |
| Soligenix, Inc. | -7.85 Million USD | 68.113% |
| Century Therapeutics, Inc. | -121.2 Million USD | 97.934% |
| Kura Oncology, Inc. | -164.95 Million USD | 98.482% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 96.874% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 75.173% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -161.457% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 41.887% |
| Autolus Therapeutics plc | -156.77 Million USD | 98.403% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 97.042% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 96.371% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 87.438% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 98.677% |
| GRI Bio, Inc. | -10.89 Million USD | 77.023% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 44.547% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 97.956% |
| IGM Biosciences, Inc. | -253.35 Million USD | 99.012% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 97.587% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 93.433% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 83.666% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 84.094% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 95.595% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 97.662% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 99.059% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 98.709% |
| Verastem, Inc. | -83.16 Million USD | 96.989% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 95.048% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 98.417% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 97.805% |
| Histogen Inc. | -10.5 Million USD | 76.158% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 82.464% |
| Surrozen, Inc. | -41.13 Million USD | 93.912% |
| Organovo Holdings, Inc. | -14.8 Million USD | 83.087% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 78181.603% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 95.735% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 95.118% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 88.374% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 69.968% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 98.492% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 94.916% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 89.638% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 83.367% |
| Apollomics, Inc. | -171.74 Million USD | 98.542% |
| Amarin Corporation plc | -50.9 Million USD | 95.081% |
| Mesoblast Limited | -61.33 Million USD | 95.917% |
| Turnstone Biologics Corp. | -56.23 Million USD | 95.547% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 98.251% |
| Synaptogenix, Inc. | -8.3 Million USD | 69.858% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 83.675% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 96.028% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 47.739% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 683.648% |
| Exelixis, Inc. | 196.6 Million USD | 101.274% |
| Better Therapeutics, Inc. | -38.26 Million USD | 93.455% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 98.229% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 99.494% |
| NLS Pharmaceutics AG | -11.79 Million USD | 78.771% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 1112.911% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 91.513% |
| Gritstone bio, Inc. | -126.86 Million USD | 98.026% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 96.147% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 37.397% |
| Avid Bioservices, Inc. | -11.48 Million USD | 78.189% |
| Insmed Incorporated | -654.73 Million USD | 99.618% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -11.306% |
| MediWound Ltd. | -4.89 Million USD | 48.823% |
| OmniAb, Inc. | -49.73 Million USD | 94.965% |
| Alector, Inc. | -142.89 Million USD | 98.248% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 97.069% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 95.198% |
| Zai Lab Limited | -366.57 Million USD | 99.317% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 99.138% |
| Aura Biosciences, Inc. | -83.69 Million USD | 97.008% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 98.888% |
| Immunic, Inc. | -99.11 Million USD | 97.473% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 98.098% |
| Veracyte, Inc. | -49.4 Million USD | 94.932% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 64.551% |
| FibroGen, Inc. | -261.4 Million USD | 99.042% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 77.524% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 64.234% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 86.621% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 100.173% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 90.15% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 106.277% |
| TG Therapeutics, Inc. | 26.1 Million USD | 109.594% |
| Galecto, Inc. | -37.51 Million USD | 93.326% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 93.456% |
| Fortrea Holdings Inc. | 167.3 Million USD | 101.497% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 98.135% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 91.155% |
| XBiotech Inc. | -35.76 Million USD | 92.999% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 96.147% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 96.162% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 97.603% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 90.246% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 93.873% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 99.515% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 95.53% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -4367.497% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 97.848% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 88.705% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 98.935% |
| NexImmune, Inc. | -28.16 Million USD | 91.11% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 54.682% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 78.765% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 100.054% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 90.138% |
| Scopus BioPharma Inc. | -11.71 Million USD | 78.622% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 98.01% |
| Ainos, Inc. | -8.77 Million USD | 71.457% |
| Pluri Inc. | -20.22 Million USD | 87.619% |
| Prothena Corporation plc | -190.1 Million USD | 98.683% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 98.047% |
| Celularity Inc. | -183.94 Million USD | 98.639% |
| Rallybio Corporation | -72.37 Million USD | 96.54% |
| Cue Biopharma, Inc. | -46.05 Million USD | 94.563% |
| MeiraGTx Holdings plc | -57.05 Million USD | 95.611% |
| Omeros Corporation | -163.61 Million USD | 98.469% |
| Humacyte, Inc. | -96.45 Million USD | 97.404% |
| Immunocore Holdings plc | -59.64 Million USD | 95.802% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 87.074% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 89.723% |
| Blueprint Medicines Corporation | -474.61 Million USD | 99.472% |
| CalciMedica, Inc. | -34.18 Million USD | 92.676% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 96.581% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 98.513% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 99.008% |
| Pulmatrix, Inc. | -12.64 Million USD | 80.199% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 92.404% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 97.169% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 99.505% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 97.526% |
| Cytokinetics, Incorporated | -456.68 Million USD | 99.452% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 92.497% |
| Nutriband Inc. | -5.12 Million USD | 51.109% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 94.213% |
| Vor Biopharma Inc. | -114.37 Million USD | 97.811% |
| Roivant Sciences Ltd. | -996.51 Million USD | 99.749% |
| Evogene Ltd. | -23.2 Million USD | 89.208% |
| ProKidney Corp. | -147.66 Million USD | 98.304% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 96.12% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -1535.059% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 99.557% |
| CorMedix Inc. | -48.88 Million USD | 94.878% |
| BioLineRx Ltd. | -57.06 Million USD | 95.612% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 97.759% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -1139.642% |
| Atai Life Sciences N.V. | -36.31 Million USD | 93.104% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 96.851% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 96.92% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 99.091% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 91.854% |
| MediciNova, Inc. | -9.87 Million USD | 74.655% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 98.012% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -63.644% |
| GeoVax Labs, Inc. | -26.66 Million USD | 90.61% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 98.887% |
| Biomea Fusion, Inc. | -124.62 Million USD | 97.991% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 99.242% |
| Mereo BioPharma Group plc | -26.05 Million USD | 90.39% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 98.684% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 98.911% |
| Absci Corporation | -95.45 Million USD | 97.377% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 91.66% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 97.662% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 98.927% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 89.044% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 98.795% |
| Allakos Inc. | -189.91 Million USD | 98.681% |
| Imunon, Inc. | -19.87 Million USD | 87.403% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 97.692% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 102.312% |
| BioAtla, Inc. | -122.24 Million USD | 97.952% |
| NLS Pharmaceutics AG | -11.79 Million USD | 78.771% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 84.112% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 99.166% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 93.958% |
| XOMA Corporation | -39.36 Million USD | 93.638% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 97.477% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 97.872% |
| aTyr Pharma, Inc. | -52.17 Million USD | 95.201% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 97.012% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 98.315% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 98.932% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 81.659% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 68.864% |
| Akari Therapeutics, Plc | -16.8 Million USD | 85.097% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 1426.973% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 100.554% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 60.804% |
| UroGen Pharma Ltd. | -63.83 Million USD | 96.077% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 96.313% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 65.523% |
| Orgenesis Inc. | -60.71 Million USD | 95.876% |
| Entera Bio Ltd. | -8.8 Million USD | 71.558% |
| GH Research PLC | -41.15 Million USD | 93.915% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 90.187% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 96.955% |
| Xencor, Inc. | -125.87 Million USD | 98.011% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -75.534% |
| Replimune Group, Inc. | -230.19 Million USD | 98.912% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 87.578% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 77.115% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 60.804% |
| Portage Biotech Inc. | -18.19 Million USD | 86.241% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -63.644% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 97.606% |
| OncoCyte Corporation | -23.12 Million USD | 89.171% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 77.841% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 78.143% |
| Purple Biotech Ltd. | -22.22 Million USD | 88.733% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 60.935% |
| scPharmaceuticals Inc. | -46.06 Million USD | 94.564% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 85.94% |
| HilleVax, Inc. | -132.46 Million USD | 98.11% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 76.45% |
| Tharimmune, Inc. | -9.3 Million USD | 73.082% |
| Genprex, Inc. | -31.06 Million USD | 91.938% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 98.665% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 92.014% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -227.759% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 1759.384% |
| OKYO Pharma Limited | -15.74 Thousand USD | -15803.072% |
| Savara Inc. | -59.13 Million USD | 95.765% |
| Curis, Inc. | -45.13 Million USD | 94.453% |
| Daré Bioscience, Inc. | -30.7 Million USD | 91.844% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 83.516% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 65.051% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 90.633% |
| BeiGene, Ltd. | -1.12 Billion USD | 99.777% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 84.639% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 99.418% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 97.228% |
| Erasca, Inc. | -121.31 Million USD | 97.936% |
| bluebird bio, Inc. | -167.16 Million USD | 98.502% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 44.338% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 100.807% |
| DBV Technologies S.A. | -85.98 Million USD | 97.088% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 44.338% |
| Moderna, Inc. | -3.28 Billion USD | 99.924% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 94.123% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 55.664% |
| Molecular Templates, Inc. | 1.43 Million USD | 275.11% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 95.816% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 99.232% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 98.173% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 94.713% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 98.199% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 98.784% |
| MacroGenics, Inc. | 2.01 Million USD | 224.149% |
| RenovoRx, Inc. | -11.39 Million USD | 78.015% |
| Adicet Bio, Inc. | -136.53 Million USD | 98.166% |
| Prime Medicine, Inc. | -193.75 Million USD | 98.708% |
| Aditxt, Inc. | -25.45 Million USD | 90.164% |
| Adagene Inc. | -14.95 Million USD | 83.251% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 65.745% |
| Quantum-Si incorporated | -91.8 Million USD | 97.272% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 100.351% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 101.98% |
| SciSparc Ltd. | -5.28 Million USD | 52.592% |
| Vericel Corporation | 2.86 Million USD | 187.433% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -2530.112% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 88.456% |
| Generation Bio Co. | -133.3 Million USD | 98.121% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 96.984% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 97.089% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 98.899% |
| Invivyd, Inc. | -196.61 Million USD | 98.726% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 99.331% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 73.001% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 109.222% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 75.653% |
| 2seventy bio, Inc. | -206.41 Million USD | 98.787% |
| ADMA Biologics, Inc. | 5.12 Million USD | 148.908% |
| Clene Inc. | -43.24 Million USD | 94.209% |
| Capricor Therapeutics, Inc. | -23 Million USD | 89.117% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 94.835% |
| GeoVax Labs, Inc. | -26.66 Million USD | 90.61% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 99.164% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 93.182% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 110.623% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 150.997% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 92.291% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 98.419% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 99.634% |
| Evaxion Biotech A/S | -21.4 Million USD | 88.3% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 96.23% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 98.85% |
| Trevena, Inc. | -35.28 Million USD | 92.904% |
| Surrozen, Inc. | -41.13 Million USD | 93.912% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 96.854% |
| Cingulate Inc. | -22.95 Million USD | 89.09% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 66.438% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 93.284% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 69.56% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 97.551% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 96.308% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 95.71% |
| Clearmind Medicine Inc. | -8.71 Million USD | 71.253% |
| Kronos Bio, Inc. | -121.83 Million USD | 97.945% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 96.632% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -2.567% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 97.516% |
| Statera Biopharma, Inc. | 38.93 Million USD | 106.431% |
| ImmunityBio, Inc. | -436.18 Million USD | 99.426% |
| Korro Bio, Inc. | -80.9 Million USD | 96.905% |
| Kineta, Inc. | -15.71 Million USD | 84.065% |
| BioVie Inc. | -31.95 Million USD | 92.163% |
| Codexis, Inc. | -49.28 Million USD | 94.919% |
| Celularity Inc. | -183.94 Million USD | 98.639% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 98.87% |
| Celcuity Inc. | -58.3 Million USD | 95.706% |
| Virax Biolabs Group Limited | -6.6 Million USD | 62.112% |
| Cibus, Inc. | -314.58 Million USD | 99.204% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 92.577% |
| IN8bio, Inc. | -28.5 Million USD | 91.215% |
| Kodiak Sciences Inc. | -259.02 Million USD | 99.033% |
| Annexon, Inc. | -141.57 Million USD | 98.231% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 97.776% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 96.099% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 91.042% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 98.911% |
| Eyenovia, Inc. | -24.1 Million USD | 89.612% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 105.591% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -672.863% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 96.607% |
| Arcellx, Inc. | -64.14 Million USD | 96.096% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 94.437% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 97.972% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 91.891% |
| Moolec Science SA | -52.07 Million USD | 95.191% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 95.148% |
| Geron Corporation | -174.78 Million USD | 98.567% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 93.804% |
| Royalty Pharma plc | 1.88 Billion USD | 100.133% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 97.906% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 73.144% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 87.927% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 98.492% |
| Humacyte, Inc. | -96.45 Million USD | 97.404% |
| Structure Therapeutics Inc. | -102.45 Million USD | 97.556% |
| 89bio, Inc. | -134.46 Million USD | 98.138% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 96.825% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 161.799% |
| Genelux Corporation | -24.16 Million USD | 89.638% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 92.591% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 98.468% |
| Notable Labs, Ltd. | -14.4 Million USD | 82.611% |
| Liquidia Corporation | -70.05 Million USD | 96.425% |
| Mustang Bio, Inc. | -48.06 Million USD | 94.79% |
| Immunovant, Inc. | -269.97 Million USD | 99.072% |
| Quantum-Si incorporated | -91.8 Million USD | 97.272% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 96.472% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 87.031% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 97.545% |
| Acasti Pharma Inc. | -11.3 Million USD | 77.842% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 88.747% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 83.666% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 98.81% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 41.361% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 84.231% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 91.298% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 93.238% |
| PepGen Inc. | -83.58 Million USD | 97.004% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 91.513% |
| United Therapeutics Corporation | 1.38 Billion USD | 100.181% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 89.064% |
| Solid Biosciences Inc. | -93.43 Million USD | 97.32% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 47.523% |
| Immuneering Corporation | -58.06 Million USD | 95.687% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 78181.603% |
| Silo Pharma, Inc. | -3.62 Million USD | 30.945% |
| Belite Bio, Inc | -31.52 Million USD | 92.058% |
| XOMA Corporation | -39.36 Million USD | 93.638% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 96.287% |
| Bionomics Limited | -9.83 Million USD | 74.544% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 97.018% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 92.764% |
| uniQure N.V. | -253.1 Million USD | 99.011% |
| Cassava Sciences, Inc. | -95.68 Million USD | 97.383% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 65.745% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 98.066% |
| Forte Biosciences, Inc. | -32.47 Million USD | 92.29% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 68.895% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 91.126% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -672.863% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 77.524% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 84.252% |
| Altimmune, Inc. | -87.93 Million USD | 97.152% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 97.281% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 92.764% |
| Compugen Ltd. | -12.51 Million USD | 79.993% |
| Peak Bio, Inc. | -1356.23 USD | -184535.128% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 94.847% |
| Benitec Biopharma Inc. | -22.49 Million USD | 88.866% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 98.967% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 91.227% |
| Zura Bio Limited | -60.56 Million USD | 95.865% |
| PolyPid Ltd. | -20.26 Million USD | 87.642% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 83.962% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 91.227% |
| Instil Bio, Inc. | -146.12 Million USD | 98.286% |
| argenx SE | -216.02 Million USD | 98.841% |
| Immunome, Inc. | -28.27 Million USD | 91.143% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 94.834% |
| Verona Pharma plc | -52.46 Million USD | 95.227% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 97.358% |
| Shattuck Labs, Inc. | -87.61 Million USD | 97.142% |
| CervoMed Inc. | -2.17 Million USD | -15.296% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 97.952% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 80.272% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 94.802% |
| Moolec Science SA | -52.07 Million USD | 95.191% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 85.39% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 98.08% |
| AnaptysBio, Inc. | -143.16 Million USD | 98.251% |
| Design Therapeutics, Inc. | -66.32 Million USD | 96.225% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 96.908% |
| NeurAxis, Inc. | -6.66 Million USD | 62.427% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 93.367% |
| Lumos Pharma, Inc. | -36.57 Million USD | 93.153% |
| Achilles Therapeutics plc | -70.44 Million USD | 96.445% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 97.358% |
| 180 Life Sciences Corp. | -22.13 Million USD | 88.687% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 142.957% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -2.567% |
| Nutriband Inc. | -5.12 Million USD | 51.109% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 97.718% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 95.483% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 95.046% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 96.164% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 95.372% |
| Palisade Bio, Inc. | -12.28 Million USD | 79.61% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 94.481% |
| Beam Therapeutics Inc. | -156.47 Million USD | 98.4% |
| Neurogene Inc. | -52.28 Million USD | 95.211% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 98.165% |
| AEON Biopharma, Inc. | -48.36 Million USD | 94.822% |
| Sesen Bio, Inc. | -50.84 Million USD | 95.075% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 96.944% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 79.724% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 99.414% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 97.62% |
| Athira Pharma, Inc. | -116.7 Million USD | 97.854% |
| Vaccinex, Inc. | -19.74 Million USD | 87.32% |
| HCW Biologics Inc. | -23.57 Million USD | 89.379% |
| XOMA Corporation | -39.36 Million USD | 93.638% |
| Nektar Therapeutics | -243.1 Million USD | 98.97% |
| Arvinas, Inc. | -394.8 Million USD | 99.366% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 1426.973% |
| Merus N.V. | -149.2 Million USD | 98.322% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 97.322% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 91.99% |
| Rezolute, Inc. | -68.42 Million USD | 96.34% |
| Clene Inc. | -43.24 Million USD | 94.209% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 83.763% |
| BeyondSpring Inc. | -21.54 Million USD | 88.375% |
| Synlogic, Inc. | -55.16 Million USD | 95.46% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 79.276% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 76.47% |
| Peak Bio, Inc. | -1356.23 USD | -184535.128% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 92.287% |
| Krystal Biotech, Inc. | 17.9 Million USD | 113.986% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 97.885% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 99.266% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 45.64% |
| MannKind Corporation | 15.12 Million USD | 116.552% |
| Ikena Oncology, Inc. | -74.39 Million USD | 96.634% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 80.115% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 112.319% |
| Gossamer Bio, Inc. | -172.15 Million USD | 98.545% |
| CohBar, Inc. | -12.06 Million USD | 79.246% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 90.184% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 91.66% |
| Legend Biotech Corporation | -477.87 Million USD | 99.476% |
| Mural Oncology plc | -192.72 Million USD | 98.701% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 97.804% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 84.49% |
| Disc Medicine, Inc. | -91.02 Million USD | 97.249% |
| Champions Oncology, Inc. | -5.05 Million USD | 50.454% |
| REGENXBIO Inc. | -239.46 Million USD | 98.954% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 76.637% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 95.509% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 93.541% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 97.78% |
| Vaxart, Inc. | -74.72 Million USD | 96.649% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 92.888% |
| Cellectis S.A. | -98.09 Million USD | 97.447% |
| Longeveron Inc. | -20.06 Million USD | 87.517% |
| Repare Therapeutics Inc. | -114.27 Million USD | 97.809% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 99.43% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 96.653% |
| Revolution Medicines, Inc. | -430.58 Million USD | 99.418% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 60.183% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 91.867% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 96.643% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 151.072% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 77.163% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 100.054% |
| Denali Therapeutics Inc. | -179.97 Million USD | 98.609% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -2530.112% |
| Veru Inc. | -89.97 Million USD | 97.217% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 90.684% |
| Cingulate Inc. | -22.95 Million USD | 89.09% |
| Passage Bio, Inc. | -98.34 Million USD | 97.454% |
| Context Therapeutics Inc. | -25.06 Million USD | 90.008% |
| Exicure, Inc. | -15.53 Million USD | 83.885% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 98.785% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 93.228% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 58.004% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 98.514% |
| Nuvalent, Inc. | -149.49 Million USD | 98.325% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 69.209% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 97.085% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 91.702% |
| OmniAb, Inc. | -49.73 Million USD | 94.965% |
| Anew Medical, Inc. | -1.3 Million USD | -92.497% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 79.747% |
| Lipocine Inc. | -16.32 Million USD | 84.659% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 96.244% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 96.63% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 93.433% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 93.582% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 88.712% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 99.541% |
| Ocugen, Inc. | -64.82 Million USD | 96.137% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 97.295% |
| Q32 Bio Inc. | -86.5 Million USD | 97.105% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 85.207% |
| Alumis Inc. Common Stock | -156.89 Million USD | 98.404% |
| Equillium, Inc. | -12.13 Million USD | 79.37% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 95.717% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 68.316% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 86.724% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 94.637% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 97.645% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 86.0% |
| Dominari Holdings Inc. | -22.44 Million USD | 88.841% |
| Edesa Biotech, Inc. | -8.19 Million USD | 69.426% |
| vTv Therapeutics Inc. | -25.41 Million USD | 90.146% |
| Bio-Techne Corporation | 326.66 Million USD | 100.767% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 99.349% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 101.157% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 98.09% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 93.31% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 98.343% |
| Nkarta, Inc. | -120.48 Million USD | 97.922% |
| BioCardia, Inc. | -11.56 Million USD | 78.338% |
| Iterum Therapeutics plc | -34.58 Million USD | 92.759% |